CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

CSL) reported a rise in half-year net profit, driven primarily by robust performance in its blood plasma division. The company's CSL Behring unit, which focuses on plasma-derived therapies ...

Learn More CSL Ltd (ASX: CSL) shares couldn't avoid the broader market sell-off on Monday. Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock ended the day down 1.4%, trading for $276.42 apiece.

Learn More If you have been thinking about buying CSL Ltd (ASX: CSL) shares, then read on. That's because Goldman Sachs has just named another reason to buy the biotechnology giant's shares.

In a pioneering approach to achieve fusion energy, the SMART device has successfully generated its first tokamak plasma. This step brings the international fusion community closer to achieving ...

The Experimental Advanced Superconducting Tokamak (EAST), often referred to as China’s 'artificial sun,' successfully sustained plasma for a record 1,000 seconds, or over 17 minutes. This ...

Plasma collections & margin recovery in focus By contrast, CSL’s plasma arm – CSL Behring – emerged as key to current support for the company and its outlook. Immunoglobulin sales remain strong, with ...